Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia

The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model

(2014) K A Beckwith et al.   LEUKEMIA

Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells

(2013) Bo Yu et al.   BIOMATERIALS

Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

(2013) M. Hudecek et al.   CLINICAL CANCER RESEARCH

Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future

(2013) Alexey V. Danilov   CLINICAL THERAPEUTICS

Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells

(2013) Mohammad Hojjat-Farsangi et al.   PLoS One

The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells

(2013) Mohammad Hojjat-Farsangi et al.   PLoS One

ROR1 can interact with TCL1 and enhance leukemogenesis in E -TCL1 transgenic mice

(2013) G. F. Widhopf et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals

(2012) Rosa Lapalombella et al.   CANCER CELL

Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells

(2012) A H Daneshmanesh et al.   LEUKEMIA

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies

(2012) Amir Hossein Daneshmanesh et al.   LEUKEMIA & LYMPHOMA

Targeting malignant B cells with an immunotoxin against ROR1

(2012) Sivasubramanian Baskar et al.   mAbs

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

(2011) L. Alinari et al.   BLOOD

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma

(2011) Hany A. Omar et al.   HEPATOLOGY

ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia

(2011) H. Elizabeth Broome et al.   LEUKEMIA RESEARCH

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies

(2011) Jiahui Yang et al.   PLoS One

FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma

(2010) Q. Liu et al.   CLINICAL CANCER RESEARCH

Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid

(2010) Hong Li et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C   Signaling

(2008) J.-H. Hung et al.   CANCER RESEARCH

Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia

(2008) S. Baskar et al.   CLINICAL CANCER RESEARCH

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy

(2008) Amir H. DaneshManesh et al.   INTERNATIONAL JOURNAL OF CANCER

Nanoparticle therapeutics: an emerging treatment modality for cancer

(2008) Mark E. Davis et al.   NATURE REVIEWS DRUG DISCOVERY

Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL

(2008) Y. Pekarsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA